China Medicine Corporation (NASDAQ: CHME) (CMC) was established in 2005 with the goal to become a leading, research-driven pharmaceutical company dedicated to the discovery, development, manufacturing and distribution of pharmaceutical and nutritional supplement products throughout China. To fulfill this mission, CMC acquired Guangzhou Konzern Medicine Co., Ltd. in 2007.

Through its wholly-owned subsidiary, Guangzhou Konzern, CMC now distributes about 1,500 pharmaceutical products in the People’s Republic of China to a network of nearly 300 hospitals, 500 pharmaceutical companies and 1,700 drug stores. Not only does the company offer prescription and over-the-counter pharmaceutical products, traditional Chinese medicines, dietary supplements and medical instruments, it is also involved in the sale of medical formula and the development of new products.

CMC’s cocktail of experience in Western management skills, a large distribution network, advanced technology, and capital resources creates an undeniable presence on the global pharmaceutical market. The Chinese healthcare industry is expected to become one of the largest in the world, and according to the company’s Web site, “CMC aims to take advantage of the conditions within the industry and the surging demand for pharmaceutical and nutritional supplements products fueling economic growth.”

Let us hear your thoughts: China Medicine Corporation Message Board